537P - Circulating microRNA-126 and epidermal growth factor-like domain 7 protein predict recurrence of colon cancer in patients treated with neoadjuvant...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Colon and Rectal Cancer
Presenter Torben Hansen
Citation Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370
Authors T.F. Hansen1, A.L. Carlsen2, J.T. Tanassi2, N.H..H. Hegaard2, F.O. Larsen3, F.B. Soerensen4, L.H. Jensen1, A. Jakobsen1
  • 1Oncology, Danish Colorectal Cancer Center South, 7100 - Vejle/DK
  • 2Autoimmunology And Biomarkers, Statens Serum Institut, Copenhagen/DK
  • 3Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 4Clinical Pathology, Danish Colorectal Cancer Center South, 7100 - Vejle/DK

Abstract

Background

Neoadjuvant chemotherapy represents a new treatment approach for patients with locally advanced colon cancer. The aim of this study was to analyze the prognostic impact of circulating microRNA-126 (miRNA-126) and epidermal growth factor-like domain 7 (EGFL7) in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy.

Methods

All 71 patients from a phase II trial were included. Sampling of peripheral blood was carried out before initiation of neoadjuvant chemotherapy, before operation, and at the first post-operative control. The diagnostic biopsy and the resected tumour were sampled for tissue analyses. Circulating (cir-) EGFL7 was analysed in serum by enzyme-linked immunosorbent assay (ELISA) while cir-miRNA-126 was analysed by real-time qPCR based on plasma samples. The tissue expression of miRNA-126 was assessed using in situ hybridization and image guided analyses.

Results

After a median follow-up of 4.0 years, disease had recurred in 14 patients. The 5-year disease free survival (DFS) and overall survival (OS) rates were 80% and 85%, respectively. Overall, cir-miRNA-126 and cir-EGFL7 decreased during neoadjuvant chemotherapy. Patients with disease recurrence were characterized by a significantly lower miRNA-126 expression in the diagnostic biopsy (p = 0.049), and significantly lower levels of cir-miRNA-126 at baseline (p = 0.020), operation (p = 0.042), and control (p = 0.001), compared to patients without disease recurrence. High levels of cir-EGFL7, assessed before operation, were associated with a higher recurrence rate (p = 0.019). These differences translated into significant differences in DFS and OS as well. A 5-year OS rate of 96% was demonstrated for patients with cir-miRNA-126 levels above the median.

Conclusions

Low levels of miRNA-126 and high levels of EGFL7 seem to correlate with disease recurrence in patients with locally advanced colon cancer treated with neoadjuvant chemotherapy. These results are in accordance with previous studies in the adjuvant and metastatic setting collectively arguing for a clinical importance of these proangiogenic factors.

Clinical trial identification

ClinicalTrials.gov Identifier:NCT01108107

Legal entity responsible for the study

Department of Oncology, Vejle Hospital

Funding

Department of Oncology, Vejle Hospital

Disclosure

All authors have declared no conflicts of interest.